Asset Details
Do you wish to reserve the book?
Sparse item testing of clinical scales in neurology trials to alleviate burden to patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sparse item testing of clinical scales in neurology trials to alleviate burden to patients
Do you wish to request the book?
Sparse item testing of clinical scales in neurology trials to alleviate burden to patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sparse item testing of clinical scales in neurology trials to alleviate burden to patients
2024
Overview
Background
Neurology trials typically rely on composite scales for measuring symptom severity. Completing all items in a long scale can be burdensome for patients, caregivers, and trial personnel.
Objectives
To test the hypothesis that sparse item testing, aided by item-response modelling, can preserve the power for detecting treatment effect in a controlled trial.
Methods
UPDRS (Unified Parkinson’s Disease Rating Scale) Part III (motor examinations) data from a placebo-controlled trial (
N
= 391) of ropinirole were analysed with a longitudinal item-response model. Symptom severity was estimated directly from item scores as a latent variable, without needing the total score. This enabled sparse item testing. With the symptom severity as a clinical endpoint, the potential power loss for detecting treatment effect due to the sparse testing was assessed by simulation.
Results
When each patient took 18 of all 27 tests in UPDRS Part III at each study visit, there was no appreciable power loss. Reducing four visits to three also had negligible effects on power. A threefold reduction of the total tests that each patient needed to do throughout the trial, from 108 to 27, only compromised power slightly, e.g., from 92 to 87% at
N
= 160.
Conclusions
These findings show that using the symptom severity derived from item scores as the endpoint allows sparse testing to drastically reduce trial burden without incurring major power loss. This benefit would multiply for indications like Alzheimer’s disease where modern trials often require patients to be tested on multiple scales at several times.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
